The end in drug price negotiations in Germany? The “mystic” arbitration board?!

Within the German pharmaceutical market access process a core component is the price negotiation which follows in the second part of the evaluation. Negotiations will be conducted between pharmaceutical company and the Head Association of the Statutory Health Insurance Funds. In case no agreement is reached, each party could call the arbitration board which could then come up with a price agreement. The presenters will discuss the decisions of the last 10 years and potential implications. Furthermore, Prof. Wasem as the former head of the arbitration board will discuss the view of it and his experience.

Register now!

MArS goes Clubhouse (again) – 10 years AMNOG

After a great webinar on “10 years AMNOG” on Thursday evening, we are happy to announce that the discussions are expanded into the German-speaking community! MArS Market Access & Pricing Strategy GmbH goes (again) to Clubhouse!! The session on April 1 2021 will be recorded and made available afterwards as well – but even better, join us and discuss directly with well-known experts: Dr. Stefan Walzer, Prof. Dr. David Matusiewicz, Bibiane Schulte-Bosse, Dr. Mathias Flume, Heiko Schellhorn, Prof. Dr. Thomas Hammerschmidt – moderation as always by Lutz Vollmer!!

Join us at Clubhouse!!

10 years AMNOG – what have we learnt for drug development and pricing?

10 years ago, the German reimbursement system for drugs changed significantly. The AMNOG including a benefit assessment and price negotiation was launched. Threats were seen, but also opportunities – the AMNOG frame was criticized and in some aspects also changed over time. A learning system – as some say.
The speakers have worked and shaped the AMNOG process also before its implementation and have also been working since the start of it in various roles and on different products. The presentation and discussions will shows the following key aspects:

  • What are key success factors for a optimal AMNOG process?
  • Are there any guidances for clinical development?
  • How is the benefit rating and price negotiation correlated? What are drivers?
  • What can we expect in the future from the AMNOG?

Register now!

Innovative price contracting in the German AMNOG process – is this the future or just a dream?

The presenters Dr. Stefan Walzer and Roman Spelsberg analyzed the current situation of the AMNOG process with respect to price contracting. They will show opportunities and hurdles of the current system as well as current examples. Furthermore, they will also come up with a suggestion how innovative contracting could be implemented in Germany – even further…

 

Register now for our new free webinar! https://us02web.zoom.us/webinar/register/3016007018391/WN_jAWzjHTbSK2m2fUXJoqLtg

EU HTA to come?

There is a big debate since years on the potential implementation of a joint HTA system across Europe. Core questions on such a system remains on how such an approach could look like and even more important be implemented. The webinar will summarize the current status of the debate and also suggest a way how such a joint HTA could be implemented in the European Union.

Register now: https://us02web.zoom.us/webinar/register/4715954498495/WN_8WnsBaNyQZKf4BFvtgBP4g

MArS teaching at the MedTech Startup School in Tuebingen / Germany

At the start of a product’s lifecycle there are many questions to be answered and many processes to be planned. One of the core areas to cover is pricing and reimbursement as this has a direct impact on the price and patient outreach (“availability”) and hence a company’s revenues flow. MArS is teaching the tools and processes as tutors at the Startup School Tuebingen with a variety of new companies and various bright business ideas.

With our experience in pricing planning, insurance contacts, submissions and negotiations we can help driving a company through the endeavor of market access from the early days until the end.